Information Provided By: 
Fly News Breaks for December 10, 2019
ASLN
Dec 10, 2019 | 07:28 EDT
H.C. Wainwright analyst Yi Chen raised Aslan Pharmaceuticals' price target to $5 from $2 and reiterates a Buy rating on the shares.Low-dose ASLAN004 demonstrateed positive efficacy and safety in atopic dermatitis, Chen tells investors in a research note. These early signs of efficacy are very encouraging as 200 mg is the lowest dose cohort in the study, and the observed efficacy has yet to peak, Chen tells investors in a research note.
News For ASLN From the Last 2 Days
ASLN
Apr 24, 2024 | 10:53 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals... To see the rest of the story go to thefly.com. See Story Here
